Attached files
| file | filename |
|---|---|
| EX-99.1 - NEWS RELEASE DATED OCTOBER 13, 2009. - CALECO PHARMA CORP. | exhibit99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
October 13, 2009
Date of Report (Date of
earliest event reported)
CALECO PHARMA CORP.
(Exact
name of registrant as specified in its charter)
| NEVADA | 000-51261 | 20-1147435 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| Suite 410-103 East Holly Street, | |
| National Bank Building, | |
| Bellingham, WA | 98225 |
| (Address of principal executive offices) | (Zip Code) |
(360) 306-1133
Registrant's telephone number,
including area code
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
____ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
____ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
____ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
____ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
SECTION 7 – REGULATION FD
| ITEM 7.01 | REGULATION FD DISCLOSURE. |
News Release dated October 13, 2009
Attached as Exhibit 99.1 to this report, and incorporated by reference herein, is a news release issued by the Caleco Pharma Corp. (the “Company”) on October 13, 2009. The news release announces the initiation of a clinical study of “Lamiridosin”, a dietary supplement the Company is in the process of developing.
This information is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.
SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS |
(d) Exhibits
| Exhibit Number | Description of Exhibit |
| 99.1 | News Release dated October 13, 2009. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CALECO PHARMA CORP. | ||
| Date: October 19, 2009 | ||
| By: | /s/ John Boschert | |
| JOHN BOSCHERT | ||
| Chief Executive Officer, Chief Financial Officer, | ||
| President, Secretary and Treasurer | ||
2